NEW YORK (GenomeWeb) – Sciex and Hepregen today announced that they have signed a co-marketing agreement, under which the companies will bundle certain of their technologies together as a metabolite identification (MetID) solution for drug metabolism researchers.
The new offering centers around Hepregen's HepatoPac kit, an in vitro liver model comprising cryopreserved primary hepatocytes from a human, rat, monkey, or dog that are micropatterned onto microwell plates. It also includes Sciex's TripleTOF 6600 LC-MS system, as well as its Swath Acquisition data-capture method and MetabolitePilot software.
Specific terms of the arrangement were not disclosed.
"Until now, particularly in the case of low-turnover compounds, drug metabolism researchers have had significant difficulty predicting in vitro metabolic outcomes with complete confidence," Joe Fox, senior director of Sciex's pharma business, said in a statement. "Together with Hepregen, we have established this much needed end-to-end solution for our MetID customers."